Navigation Links
Safety of Labor-Delaying Drugs Questioned
Date:3/6/2009

The dilemma, researchers say, is whether or not to treat at all

FRIDAY, March 6 (HealthDay News) -- Certain drugs used to delay preterm labor can cause serious complications in women, a European study finds.

Doctors use tocolytic drugs to delay labor for up to 48 hours. In this way, they gain time to allow steroids to hasten fetal lung development. These delays also enable the expectant mother to be transferred to a medical facility with a neonatal intensive care unit, according to background information in the study.

The most widely used tocolytic drugs include beta agonists and nifedipine (which relax smooth muscles, including the uterus), and atosiban and indometacin (which inhibit hormones involved in labor), according to the study. However, the use of these drugs is controversial, because it's not clear whether tocolysis is safe for both mother and baby.

The researchers analyzed the rate of serious complications in 1,920 women treated with tocolytic drugs for preterm labor at 28 hospitals in the Netherlands and Belgium. Atosiban was the most commonly used drug (42 percent), followed by nifedipine (34 percent), beta agonists (14 percent), and indometacin (8 percent).

The overall incidence of adverse effects was 0.7 percent, but combined or single treatment with a beta agonist led to a higher incidence of serious drug reactions. There were no reports of serious reactions when women received atosiban or indometacin.

Combined or single treatment with beta agonists should be discouraged, concluded the researchers. They also recommended further trials to test the safety and effectiveness of nifedipine and atosiban.

In an accompanying editorial, the researchers said their study is a reminder that the decision to use tocolysis shouldn't be taken lightly.

"After 30 years of research, we still do not know whether tocolysis benefits the fetus, so the choice of which drug to use remains a secondary question. The real dilemma is whether or not we should treat at all," they wrote. The long-held belief that "keeping the baby inside longer must be a good thing" needs to be reevaluated, they said.

The study was published March 6 online in the BMJ.

A study released last year found that nifedipine was no more effective than placebo at preventing preterm labor. The U.S. study, which included 71 women, was published in the journal Obstetrics & Gynecology.

More information

The U.S. National Institute on Child Health and Human Development has more about preventing preterm birth.



-- Robert Preidt



SOURCE: BMJ, news release, March 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. AdvaMed Available for Comment on Medical Device Safety Act
2. AdvaMed Response to the Medical Device Safety Act
3. bioPoint(TM) PID Wristband Software Improves Patient Identification Accuracy and Safety
4. New Esco White Papers Document Hydrogen Peroxide Decontamination of Biological Safety Cabinets
5. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
6. Zebra Technologies Introduces New Soft Infant Wristbands for Improved Safety and Comfort
7. Travel Safety Can Be a Passport to Good Health
8. Main U.S. Toxics Law Failing to Ensure Safety of Thousands of Chemicals
9. Johns Hopkins safety team works to eliminate bloodstream infections in the nation and the world
10. Governor Rendell Forms Food Safety Council to Protect Public Health, Food Supply
11. Switch to Daylight Savings Time Will Launch First Annual Sedation Dentistry Safety Week Hosted by DOCS Education
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Safety of Labor-Delaying Drugs Questioned
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international ... travel, spa and beauty in Europe. The organization asked its partner experts in Europe ... researchers - to forecast where wellness is headed in Europe. Predictions range from European ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... The Orthopaedic ... executive committee members: , David G. Lewallen, MD, began his term as president ... president. Michael L. Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, will ...
(Date:5/31/2016)... , ... May 31, 2016 , ... In a recent ... Feiner and broadcast on New Rochelle, NY-based WVOX (1460 AM), leading medical ... what she calls the country’s “modern medical money maelstrom.” , During the interview ...
(Date:5/31/2016)... ... May 31, 2016 , ... To meet a growing demand ... industry, The University of Scranton is adding a Certificate in Health Informatics to ... in rapidly growing field of healthcare information. , Healthcare organizations are under ...
(Date:5/30/2016)... , ... May 30, 2016 , ... ... use inside of FCPX," said Christina Austin - CEO of Pixel Film Studios. ... use within Final Cut Pro X. Choose from abstract transitions to more simple ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 2016 RnRMarketResearch.com adds "Asthma - ... analysis of Asthma therapy at various stages, therapeutics assessment ... administration (RoA) and molecule type, along with latest updates, ... key players involved in the therapeutic development for Asthma ... Complete report on H1 2016 pipeline review of ...
(Date:5/30/2016)... 2016 According to a ... Market by Type (Stability, Raw Materials, Method Validation, ... (Pharmaceutical Companies, Medical Device Companies) - Global Forecast ... healthy growth during the last decade and is ... between 2016 and 2021 to reach USD 4.13 ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for ... Stempeucel® becomes 5th off-the-shelf Stem cell product to be approved by ... Disease (also known as Thromboangiitis Obliterans) is a major unmet medical ... - Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... the European Community & USA ...
Breaking Medicine Technology: